PF-06273340

Catalog No.S8407 Batch:S840702

Print

Technical Data

Formula

C23H22ClN7O3

Molecular Weight 479.92 CAS No. 1402438-74-7
Solubility (25°C)* In vitro DMSO 95 mg/mL (197.94 mM)
Ethanol 4 mg/mL (8.33 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description PF-06273340 is a highly potent, kinases elective, well-tolerated pan-Trk inhibitor with IC50 values of 6, 4, 3 nM for TrkA, TrkB, Trk C, respectively.
Targets
TrkC [1]
(Cell-free assay)
TrkB [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
3 nM 4 nM 6 nM
In vitro PF-06273340 is a highly potent pan-Trk inhibitor, with an excellent LipE profile. PF-06273340 is profiled in a series of in vitro safety assays, showing little cytotoxicity in THLE or HepG2 cell lines (IC50 > 42 μM and >300 μM, respectively). In this broad panel, all IC50/Ki values were >10 μM except for COX-1 (IC50 = 2.7 μM) and dopamine transporter assays (Ki = 5.2 μM) and PDEs 4D, 5A, 7B, 8B, and 11 (54−89% inhibition at 10 μM). PF-06273340 is screened in the Invitrogen wide kinase panel of 309 kinases, and all were inhibited by <40% when tested at 1 μM except the following: MUSK (IC50 53 nM), FLT-3 (IC50 395 nM), IRAK1 (IC50 2.5 μM), MKK (90% @ 1 μM), and DDR1 (60% @ 1 μM)[1].
In vivo In rats, decreases in white blood cell count are observed from 150 mg/kg/day. At doses ≥250 mg/kg, increases in body weight gain and food consumption are observed, effects that could be rationalized as being mediated by central inhibition of TrkB, agonists of which are known to be anorexigenic in rodents. Adaptive changes in the liver are observed microscopically and accompanied by increased liver weight at ≥250 mg/kg and increases cholesterol at 1000 mg/kg. Overall, PF-06273340 is well tolerated up to 1000 mg/kg/day where plasma exposure (unbound Cavg) is approximately 400×TrkA IC50[1].

Protocol (from reference)

Animal Study:

[1]

  • Animal Models

    Male SD rats

  • Dosages

    0.25, 2.5 and 25 mg/kg

  • Administration

    oral administration

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.